Medline Industries recalled 104,608 units of sterile saline wound wash on January 5, 2026. The product may not have met the required sterility assurance level. Consumers should stop using this product immediately and follow recall instructions.
Medline has identified that the manufacturer of the sterile saline wound wash may not have manufactured products to meet the minimum required sterility assurance level required for sterile products.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Medline Industries, LP or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is Meijer STERILE saline wound wash, First Aid Cleansing Spray, model number MJSALINE7. It comes in a 7.1 FL OZ (210 mL) spray can. The product was distributed worldwide, including the US, Bahamas, Bermuda, and Cayman Islands.
Medline identified that the manufacturer may not have produced the saline wound wash to meet the minimum required sterility assurance level. This poses a risk of infection and other complications associated with non-sterile medical products.
No specific incidents or injuries have been reported related to this recall. However, the potential for serious health risks exists due to the sterility issue.
Stop using the saline wound wash immediately. Follow the recall instructions provided by the manufacturer and contact Medline Industries for further guidance.
For more information, contact Medline Industries at their official website or customer service. Details about the recall can be found at the FDA website.
Get instant alerts for recalls that affect you. Free forever.
AvKARE recalled Amantadine HCl capsules on February 13, 2026, due to failed dissolution specifications. The recall affects the 100 mg capsules, which may not dissolve properly. Consumers should stop using this product and contact their healthcare provider immediately.
Slate Run Pharmaceuticals recalled Eptifibatide Injection on February 12, 2026. The recall affects all lots of the 75 mg/100 mL vial due to incorrect dosing information. Healthcare providers and consumers must stop using the product immediately.
LEO Pharma Inc. recalled 11,407 units of Adbry injection on February 10, 2026. The recall stems from a lack of assurance of sterility due to particulate matter identified as wool fiber. Consumers should stop using the product immediately and contact their healthcare provider for guidance.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Hitachi Ltd. recalled one unit of its Proton Beam Therapy System on February 6, 2026 due to a software anomaly. The issue may result in positional discrepancies during patient treatment. The recall affects distribution in Texas and Washington D.C.
Hitachi recalled its Proton Beam Therapy System on February 6, 2026, due to a software anomaly that may result in positional discrepancies. The recall affects one unit distributed in Texas and Washington D.C. Healthcare providers and patients must stop using the device immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.